

Global TB Drug Pipeline

Discovery¹

Preclinical Development

Clinical Development

Lead Optimization

Preclinical Development

GLP Tox.

Phase I

Phase II

Phase III

Mycobacterial Gyrase Inhibitors

CPZEN-45

BTZ043

AZD5847

Bedaquiline (TMC-207)

Gatifloxacin

Riminophenazines

SQ641

PA-824

Moxifloxacin

Diarylquinoline

SQ609

Linezolid

Rifapentine

Translocase-1 Inhibitor

DC-159a

Sutezolid (PNU-100480)

Delamanid

Q201

SQ-109

(OPC67683)

MGyrX1 inhibitor

THPP

Rifapentine

InhA Inhibitor

TBA-354

Novel Regimens²

GyrB inhibitor

LeuRS Inhibitor

Pyrazinamide Analogs

Chemical classes:

fluoroquinolone, rifamycin, oxazolidinone, nitroimidazole, diarylquinoline, benzothiazinone

¹ Ongoing projects without a lead compound series can be viewed at <http://www.newtbdrugs.org/pipeline-discovery.php>

² Combination regimens: first clinical trial (NC001) of a novel TB drug regimen testing the three drug combination of PA-824, moxifloxacin, and pyrazinamide.



www.newtbdrugs.org

Updated: November 2, 2011